The physician has a unique perspective that non-clinical investors don’t: they know firsthand whether a technology will be adopted. They deeply understand if it truly is better for them and their patients.
The physician has a unique perspective that non-clinical investors don’t: they know firsthand whether a technology will be adopted. They deeply understand if it truly is better for them and their patients.
Originally CE marked in 2021 for limited to high-risk patients only, .Abbott has now received CE mark approval for its Navitor transcatheter aortic valve replacement (TAVR) system to treat low- and intermediate-risk patients with symptomatic, severe aortic stenosis.
A comprehensive update on the combination products market shows significant industry partnerships, development challenges, and strategic imperatives for success in the sector characterized by dynamic collaboration between pharmaceutical and device companies, rapid product development cycles, and complex regulatory landscapes.
Shift Left, an approach to revenue cycle, may help clinics reimagine billing – not as a back-end cleanup job, but as something solved upstream at registration, like eligibility checks and authorizations – before a single claim is ever submitted. Are fewer denials, faster payments, and stronger financial footing possible for clinics already stretched thin?
Recor Medical Announces Paradise Ultrasound Renal Denervation System Receives Manufacturing and Marketing Approval in Japan for the Treatment of Resistant Hypertension.
Terumo Corporation is acquiring OrganOx Limited to enhance organ preservation technology and address transplant challenges globally. Acquisition marks Terumo entry into transplant sector.
While Zimmer has been able to maintain the largest market share over the past decade, competition in the knee reconstruction space is no longer limited to pricing or incremental design improvements. It is evolving into a battle of technological sophistication and long-term clinical outcomes.
The company initiated trials for AGENT DCB, a drug-coated coronary balloon approved for use in the U.S. and currently indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.
According to Company, the patent has profound business implications for Inspira and for its ability to dominate a market with a potential size of $20 billion.
The companies have reached a long-term agreement allowing customers to use software, data, technology, and service offerings from Veeva and IQVIA together.